Cite
HARVARD Citation
Gooderham, M. et al. (2022). Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. pp. 855-865. [Online].